COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : Le Nexviazyme de Sanofi a atteint tous les critères d’évaluation principaux et secondaires dans une étude de phase III sur la forme infantile de la maladie de Pompe
30/06/2026
Le Nexviazyme de Sanofi a atteint tous les critères d’évaluation principaux et secondaires dans une étude de phase III sur la forme infantile de la maladie de Pompe Le Nexviazyme a atteint son objectif principal, à [...]
Addex Shareholders Approve All Resolutions at Annual General Meeting
30/06/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market
30/06/2026
ORION CORPORATION PRESS RELEASE 30 JUNE 2026 at 8.00 EEST Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market Orion Pharma (“Orion”) and Shilpa Biologicals Private Limited [...]
Le Centre National de Protonthérapie du Portugal sera équipé de deux solutions Proteus®ONE d’IBA
30/06/2026
Louvain-la-Neuve, Belgique, le 30 juin 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
The National Proton Therapy Center of Portugal will be equipped with two IBA Proteus®ONE solutions
30/06/2026
Louvain-La-Neuve, Belgium, June 30, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment [...]
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
30/06/2026
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve [...]
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
30/06/2026
The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED [...]
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
30/06/2026
FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune [...]
Twentyeight Health partners with Clue to expand access to affordable birth control nationwide
29/06/2026
Bridging the gap between daily cycle tracking and provider-led contraceptive care for personalized reproductive health NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Twentyeight Health, the leading women's telehealth [...]
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
30/06/2026
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the [...]
PetVivo Reports Financial and Operational Results for Fiscal 2026
29/06/2026
MINNEAPOLIS, MN, US, June 29, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, [...]
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
29/06/2026
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and [...]
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
29/06/2026
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free [...]
Dragon Pharma Store Announces Expansion of Research Product Catalog with Addition of KLOW 80mg
29/06/2026
New York, USA, June 29, 2026 (GLOBE NEWSWIRE) -- Dragon Pharma Store announced the addition of KLOW 80mg to its online research product catalog, reflecting continued expansion of available laboratory research materials [...]
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
29/06/2026
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database [...]
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
29/06/2026
FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement- [...]
Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité
29/06/2026
Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité L’obéfazimod a apporté [...]
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
29/06/2026
FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision [...]
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
29/06/2026
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system SARASOTA, FLA., June 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a [...]

Pages